hotspot -WSS

hotspot

author：fashion 2025-09-28 10:52:51 - browse：24476

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： iTeos Therapeutics debuts first data on TIGIT

WSS

Report: NIH

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Akili, maker of video game for ADHD, to be acquired for 34 million

Change Healthcare outage fallout shows need for new oversight

Do more moles mean more problems? Not so, says new study

As AI in medicine takes off, can 'human in the loop' prevent harm?

entertainment

hotspot

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Dark money group runs ads on China biotech bill

At least 13 dead in Texas as scorching temps continue

AI used to predict Covid

23andMe had bad news about my health. I wish a person had delivered it

Do more moles mean more problems? Not so, says new study

Wildfire smoke exposes gaps in outdoor worker protections

Startling documents reveal new facets of Sacklers' opioid empire

Activists slam private health insurers over coverage restrictions

Average age of first period drops to 11.9 years, study shows

focus

WuXi out of biotech trade group, U.S. and China relations to blame

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

How to save health care price transparency rules

Scientists successfully use ultrasound imaging to map brain activity

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

entertainment

Wikipedia

entertainment

entertainment